Jul 16, 2018
1. Featured Article: Longitudinal analysis of impulse control disorders in Parkinson disease2. What's Trending: Frontiers in Neuroscience plenary interview from 2018 Annual MeetingThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the July 17, 2018 issue of Neurology. In the first segment, Dr. Jason Crowell talks with Dr. Alexis Elbaz about his paper on impulse control disorders in Parkinson disease. In the second part of the podcast, Dr. Alberto Espay focuses his interview with Dr. Jeff Lichtman on connectomics. The interview was recorded at the 2018 AAN Annual Meeting in Los Angeles.DISCLOSURES: Drs. Crowell and Lichtman reports no disclosures. Dr. Elbaz has received research support from Agence nationale de la recherche (ANR), Agence nationale de sécurité du médicament et des produits de santé, JPND (Joint Programme - Neurodegenerative Disease Research), Institut de santé publique (IRESP), French ministry of agriculture, and Anses (government agency for food and environment safety). Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH.